Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Sarcoma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Urogenital Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Squamous Cell 1Multiple Myeloma 1Microsatellite Instability 1Mesothelioma 1Histiocytoma, Malignant Fibrous 1Giant Cell Tumor of Bone 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

fludarabine 1aldesleukin 1Radiosurgery 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Ipilimumab 1Immunotherapy 1Genetic Testing 1Drug Therapy 1Cyclophosphamide 1CTLA-4 Antigen 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × fludarabine × Endocrine × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡